Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
...CR2-fH substantially reduced disease activity and joint damage... An inhibitor of the alternative pathway (AP) of complement activation reduces clinical disease activity and joint damage in an ...
Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB ...
RESEARCH TRIANGLE PARK, N.C., Aug. 26, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its oral Factor D inhibitor, BCX9930, demonstrated >99 percent ...
The lectin pathway is the third pathway in the complement cascade, discovered after the classical and alternative pathways. It more closely resembles the classical pathway due to similar binding ...
The current coronavirus disease 2019 (COVID-19) pandemic, which is due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 5.5 million casualties to date. Despite ...
While the world waits eagerly for a safe and effective vaccine to prevent infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the COVID-19 pandemic, ...
- Adds clinical-stage portfolio of oral small molecule Factor D inhibitors to Alexion’s pipeline - - Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback